




Report on the Progress of Pandemic Influenza (H1N1) Vaccination in the Region of the Americas 16 July 2010

1) Advances in Vaccination Campaigns

Figure 1. Vaccination Coverage by Risk Group in Selected Countries of Latin America and the Caribbean According to Established Vaccination Goals.



As of 16 July, twenty-nine countries in the Region of the Americas have administered 187,856,441 million doses, especially in the prioritized groups of health care workers, pregnant women and persons with one of several chronic medical conditions. Canada has distributed approximately 24 million doses. Country vaccination coverage is presented in table 1ⁱ.

1.1) Vaccination of pregnant women.

Countries in Latin America and Caribbean (LAC) planned to vaccinate approximately 7 million pregnant women; as of 16 July approximately 63.4% of this population has been reached. Only one country has vaccinated 100% of


ⁱ Advances in vaccination by risk group and country can be found at:
http://new.paho.org/hq/index.php?option=com_content&task=view&id=2612&Itemid=2116&lang=en



all pregnant women targeted (Figure 2). Vaccine coverage among pregnant women is currently the lowest when compared with the other prioritized groups: individuals with chronic medical conditions (75.1%) and health care workers (>90%). It is necessary for countries to intensify vaccination efforts targeting pregnant women in coordination with scientific societies and civil society.

It is important to highlight that epidemiologic evidence obtained during the current influenza pandemic shows pregnant women like a group with high risk of morbidity (both for the mother and the fetus), hospitalization and death, especially in the 2nd and 3rd trimester of pregnancy and in the first two weeks post partum^{ii,iii}. The World Health Organization (WHO) has therefore recommended that all pregnant women be vaccinated with inactivated vaccine at any time point.^{iv}.

Figure 2. Influenza Pandemic Vaccination Coverage of Pregnant Women in LAC.



ⁱⁱ CDC. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care - New York City, 2009. MMWR Morb Mortal Wkly Rep. 2010 Mar 26;59(11):321-6.

ⁱⁱⁱ Siston A et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010 Apr 21;303(15):1517-25.

^{iv} WHO. Strategic Advisory Group of Experts on Immunization – report of the extraordinary meeting on the influenza A(H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol Rec. 2009;84(30):301-4.



Table 1. Vaccination Coverage by Country in the Americas.

Countries and Territories	Doses Administered	Target Population Coverage	Total Population Coverage	Prioritized Risk Groups			
				Health Personnel and Essential Services	Pregnant Women	Chronic Diseases	Others
Anguilla	-	-	-	-	-	-	-
Argentina	5,266,958	81.3%	13.2%	99.4%	85.4%	93.7%	68.7%
Bahamas	5,006	18.3%	1.5%	18.0%	18.6%	15.8%	-
Barbados	4,360	21.8%	1.7%	64.2%	3.3%	11.5%	-
Belize	416	1.1%	0.1%	-	-	-	-
Bermuda	1,053	22.7%	1.6%	-	-	-	-
Bolivia	662,900	52.6%	6.8%	54.0%	17.0%	82.0%	43.1%
Brazil	82,227,716	89.7%	42.8%	119.3%	75.0%	154.8%	73.3%
Canada	-	-	-	-	-	-	-
Cayman Islands	2,318	4.1%	4.8%	1.8%	5.6%	0.0%	5.0%
Chile	2,945,053	74.7%	17.5%	103.3%	53.7%	77.3%	73.4%
Colombia	1,479,531	72.2%	3.3%	53.4%	58.5%	101.3%	59.5%
Costa Rica	180,000	90.3%	4.0%	-	-	-	-
Cuba	1,123,526	100.1%	10.0%	101.8%	100.7%	98.8%	100.7%
Ecuador	950,444	100.6%	7.1%	-	-	-	-
El Salvador	1,167,512	79.6%	19.0%	178.2%	43.3%	-	77.0%
Guatemala	221,295	18.6%	1.6%	1	0	0	0
Guyana	121,900	76.7%	16.0%	-	-	-	-
Honduras	467,336	29.3%	6.4%	68.6%	46.9%	110.7%	0.0%
Mexico	26,903,232	96.7%	24.8%	94.9%	71.7%	101.9%	82.2%
Montserrat	1,245	77.5%	24.9%	-	-	-	-
Nicaragua	251,759	29.6%	4.4%	91.3%	88.1%	37.5%	15.7%
Panama	254,286	84.7%	7.5%	50.1%	32.1%	374.8%	85.3%
Paraguay	896,037	74.7%	14.4%	80.0%	32.5%	64.1%	83.1%
Peru	1,158,741	36.1%	4.0%	40.8%	7.3%	19.9%	176.2%
Suriname	24,674	29.0%	4.8%	23.4%	4.5%	10.4%	-
Trinidad and Tobago	23,985	34.3%	1.8%	57.0%	0.7%	-	-
United States	61,000,000	38.1%	19.6%	-	-	-	-
Uruguay	515,158	51.5%	15.4%	-	-	-	-
TOTAL	187,856,441						

(-) Not available.

2) Vaccine acquisition

2.1) PAHO Revolving Fund (RF):

24 countries have purchased 20,560,970 doses of monovalent pandemic influenza vaccine through the RF, 17,526,810 without adjuvant (Sanofi-Pasteur and Novartis) and 3,034,160 with adjuvant (Novartis).

2.2) Direct and Mixed Vaccine Purchase:

Four countries in LAC, Argentina, Brazil, Mexico and Suriname have acquired approximately 140 million vaccine doses through direct purchase from laboratories. Brazil has also purchased 10 million doses from the Revolving Fund and Suriname has received 50,000 doses donated through the WHO.



2.3) Vaccine Donation through WHO:

Eleven countries in the Region were eligible to receive pandemic influenza vaccine donated through WHO to receive a total donation of 11,074,000 doses of which 10,024,000 doses have been already deployed, as of 16 July. Haiti's final decision regarding whether to accept 1,000,000 doses offered by WHO remains pending.

2.3) Vaccine Donation from Spain:

The Spanish Government has offered a donation of 4,113,870 vaccine doses to be delivered to 5 countries in the Region (Cuba, Dominican Republic, Jamaica, Nicaragua and Panamá) with remaining vaccine gaps. Administrative procedures are in process in order to ship this vaccine to the selected countries.

3) Events Supposedly Attributable to Vaccination or Immunization (ESAVI)

With regards to ESAVI surveillance, to date, there have been 9,923 reported ESAVI, of which 411 have been classified as severe. Severe ESAVI have been reported in Argentina (47), Bahamas (2), Bolivia (2), Brazil (255), Colombia (10), Costa Rica (3), Cuba (8), Ecuador (14), Guatemala (2), Honduras (7), Mexico (28), Nicaragua (4), Panama (2), Paraguay (3), Peru (17), Suriname (3) and Uruguay (4). Out of these severe ESAVI, 127 have been classified^v as events related to pandemic Influenza (H1N1) vaccine; these have been reported in Argentina (12), Brazil (106), Cuba (3), Ecuador (1), Honduras (3), Nicaragua (1) and Peru (1). Nineteen of these cases were anaphylaxis (0.2 events per million doses). The expected anaphylaxis rate is between 1-10 cases per million doses. Twenty-eight probable cases of Guillain-Barré Syndrome (GBS) have been notified (18 from Mexico, 7 from Brazil, 2 from Argentina and 1 from Peru). Ten of these cases have been discarded, as they didn't fulfill GBS criteria (Brighton Collaboration), 3 have been classified as non-related events and the rest are under investigation. Seventy programmatic errors have been reported. All cases were followed up and none of them presented adverse reactions.

4) Technical documents and progress made in countries' vaccination campaigns are continuously updated on PAHO's Immunization website:

http://new.paho.org/hq/index.php?option=com_content&task=view&id=2461&Itemid=569&lang=en

This bulletin is updated with the information included in the country profiles sent weekly by PAHO Member States.

^v Case classification presented is preliminary, as Specialized National Committees are still working on case classification based on a complete case review.